Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview

• Published in: Diagnostics (Basel) 2024-07, Vol.14 (14), p.1519
• Main Authors: Chinnappan, Raja, Makhzoum, Tariq, Arai, Momo, Hajja, Amro, Abul Rub, Farah, Alodhaibi, Ibrahim, Alfuwais, Mohammed, Elahi, Muhammad Affan, Alshehri, Eman Abdullah, Ramachandran, Lohit, Mani, Naresh Kumar, Abrahim, Shugufta, Mir, Mohammad Shabab, Al-Kattan, Khaled, Mir, Tanveer Ahmad, Yaqinuddin, Ahmed
• Format: Article
• Language: English
• Subjects: Biological apparatus and supplies; Biological markers; Biomarkers; Biopsy; Biosensors; cancer biomarkers; Detectors; Development and progression; Genes; hepatocellular carcinoma; Hepatoma; Liver; Liver cancer; Liver cirrhosis; Liver diseases; liver diseases diagnosis; Magnetic resonance imaging; Medical prognosis; Metabolites; Methylene blue; Mutation; Nucleic acids; Pathophysiology; Patients; Prognosis; Proteins; Radiation; Risk factors; Tomography
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14141519

Hepatocellular carcinoma is currently the most common malignancy of the liver. It typically occurs due to a series of oncogenic mutations that lead to aberrant cell replication. Most commonly, hepatocellular carcinoma (HCC) occurs as a result of pre-occurring liver diseases, such as hepatitis and cirrhosis. Given its aggressive nature and poor prognosis, the early screening and diagnosis of HCC are crucial. However, due to its plethora of underlying risk factors and pathophysiologies, patient presentation often varies in the early stages, with many patients presenting with few, if any, specific symptoms in the early stages. Conventionally, screening and diagnosis are performed through radiological examination, with diagnosis confirmed by biopsy. Imaging modalities tend to be limited by their requirement of large, expensive equipment; time-consuming operation; and a lack of accurate diagnosis, whereas a biopsy's invasive nature makes it unappealing for repetitive use. Recently, biosensors have gained attention for their potential to detect numerous conditions rapidly, cheaply, accurately, and without complex equipment and training. Through their sensing platforms, they aim to detect various biomarkers, such as nucleic acids, proteins, and even whole cells extracted by a liquid biopsy. Numerous biosensors have been developed that may detect HCC in its early stages. We discuss the recent updates in biosensing technology, highlighting its competitive potential compared to conventional methodology and its prospects as a tool for screening and diagnosis.